Cathie Wood shells out $13.9 million for one high-stakes biotech stock
Amid all the noise over tariffs and rate-cut chatter, the smartest move is often to follow investors who've done it before.
💵💰💰💵
Love her or hate her, Cathie Wood is a true maverick who's made a name finding tomorrow's big disruptors long before anyone else.
Now, with a fresh swing at a major biotech stock, it says a lot about where she thinks the next big win will come from.
Cathie Wood's love affair with biotech stocks has been part of ARK's DNA since day one.
Long before CRISPR became a Wall Street buzzword, Wood's team has been busy, scooping up shares in early-stage gene-editing names.
Her Genomic Revolution ETF, ARKG, was one of ARK's first thematic funds, which made a splash by loading up on companies like Editas Medicine and Intellia Therapeutics.
The idea was clear: Programmable gene-editing tools could effectively flip medicine from symptom treatment to real cures.
That early leap paid off massively.Between 2019 and 2020, ARKG posted massive gains, led by positive trial results and big-name pharma partnerships, while broader markets were stuck in neutral.
Wood has been consistent in backing her biotech picks, regardless of bad trial news or cash crunches.
For her, the appeal of gene editing has more to do with rewriting what health care looks like. She sees CRISPR and next-gen editing tools as critical tools in curing diseases outright, cutting treatment costs, while giving patients their lives back.
Such a strategy comes with its fair share of risk, but Wood spreads that risk across multiple platforms.
For those who back game-changing science, her biotech playbook is clear and effective at spotting revolutionary picks that typically stun Mr. Market.
Cathie Wood kicked off what's been a choppy week with a classic ARK move, in loading big on a key biotech stock while locking in gains elsewhere.
On Monday, ARK Invest scooped up 659,000 shares of Beam Therapeutics () , splitting the buy between Wood's flagship ARK Innovation ETF and the ARK Genomic Revolution ETF.
More Tech Stock News:
Google's quiet AI win spells trouble for Amazon
Nvidia-backed stock sends a quiet shockwave through the AI world
Veteran Tesla analyst drops 4-word call
That comes to more than $13 million in fresh Beam stock, following a relatively smaller buy earlier this week worth roughly $571,000.
Beam Therapeutics stands out in the ARK portfolio for good reason.
Its robust base-editing technology promises remarkably more precise and safer gene edits than standard CRISPR.Instead of slicing through both strands of DNA, Beam's method efficiently swaps out tiny pieces one at a time, making it a lot safer and more precise.
That competitive edge has major stakes.
Beam's pipeline includes programs for monogenic disorders including sickle cell and beta-thalassemia, along with multiple readouts lined up for this year.
Beam's cash position is another plus for Wood, with the business funded into 2027, easing dilution fears that typically rattle biotech names.
Also, a major Pfizer partnership in cardiovascular disease adds new layers to Beam's commercial push, while landing it even more credibility on the stock market.
Hence, for Wood, Beam essentially ticks every box. Its powerful disruptive science, tangible milestones, and huge upside potential suggest a long-term winner.
It's exactly the kind of swing-for-the-fences bet ARK is famous for and has made many millionaires in the process.
On the flip side, Wood's team lightened up on Roblox () , selling 31,416 shares worth roughly $3.25 million of the popular gaming stock as it rebounded.
That follows ARK's moves last week, where it sold 26,877 shares of the gaming giant.
As always, biotech isn't for the faint-hearted, but for Cathie Wood, Beam is the moonshot that's in position to rewrite history.Cathie Wood shells out $13.9 million for one high-stakes biotech stock first appeared on TheStreet on Jul 8, 2025
This story was originally reported by TheStreet on Jul 8, 2025, where it first appeared.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
7 hours ago
- Business Insider
TER, META: Cathie Wood Continues to Bet Big on Robotics, Trims Stake in This Tech Stock
Popular investor Cathie Wood's ARK Invest made key portfolio moves on Friday, July 18, with the spotlight on a major buy in the industrial automation space. As per ARK's daily trade disclosures, the largest transaction of the day was $3 million-plus purchase in Teradyne (TER). At the same time, Wood offloaded shares of technology stock Meta Platforms (META). Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Wood Continues to Load Up on Teradyne Stock On Friday, ARK bought 39,792 shares of Teradyne, valued at $3.74 million. The buy was made through its flagship ARK Innovation ETF (ARKK). The transaction follows a sizable TER purchase on July 17 —84,000 shares for a total of $7.8 million. Teradyne is a major name in industrial automation and testing, a sector where Wood has been steadily building exposure amid rising interest in AI and robotics. With TER stock being down 25% year-to-date, Wood seems to be taking advantage of the pullback as a buying opportunity. What Is the Teradyne Stock Price Forecast for 2025? On TipRanks, Teradyne stock has a Moderate Buy consensus rating based on nine Buys, two Holds, and three Sell ratings. Also, the average TER price target of $97.15 implies a 3.44% upside potential from current levels. ARK Trims Stake in Meta Stock On the sell side, ARK continued to reduce its stake in Meta, offloading $1.5 million worth of shares through ARKK. This suggests ARK is reducing its stake in the social media giant. Year-to-date, META stock is up 20.5%. Additionally, ARK sold a small stake in Guardant Health (GH), trimming $141.6K worth of shares from its biotech-focused funds. Is Meta a Buy, Sell, or Hold? Turning to Wall Street, analysts have a Strong Buy consensus rating on META stock based on 41 Buys, four Holds, and zero Sells assigned in the past three months, as indicated by the graphic below. Furthermore, the average META price target of $743.69 per share implies 5.6% upside potential.
Yahoo
a day ago
- Yahoo
CRISPR Therapeutics (CRSP) Soars 18% After $51-Million Insider Trading
We recently published . CRISPR Therapeutics AG (NASDAQ:CRSP) is one of this week's top performers. CRISPR Therapeutics soared by 18.22 percent on Friday to close at $65.13 apiece to hit a new all-time high as investors took path from a recent insider trading that gobbled up shares worth more than $51 million in the company. In a regulatory filing, CRISPR Therapeutics AG (NASDAQ:CRSP) said its director, George Simeon, snapped up 989,812 shares of the company at a price of $52.03 apiece. The shares were all bought on Wednesday, July 16. Based on its historical earnings performance, CRISPR Therapeutics AG (NASDAQ:CRSP) is set to release the results of its second quarter earnings performance in the first week of August 2025. Copyright: kadmy / 123RF Stock Photo In the first quarter of the year, CRISPR Therapeutics AG (NASDAQ:CRSP) widened its net loss by 17 percent to $136 million from $116 million previously. Revenues, however, jumped by 71.6 percent to $865 million from $504 million year-on-year. While we acknowledge the potential of CRSP as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Yahoo
This Opportunity Could Spell Huge Success for Tesla
Key Points Tesla recently launched its robotaxi service in Texas. This could spawn a multitrillion-dollar market. These 10 stocks could mint the next wave of millionaires › Tesla (NASDAQ: TSLA) has been stealing headlines with its latest robotaxi launch in Austin, Texas. Yet shares have fallen by 20% over the past six months. If you're looking to buy into this iconic growth stock at a discount, this could be your best chance in years. Tesla's robotaxi division could lead a $10 trillion global market On the surface, Tesla shares look pricey versus the competition. Shares trade at 11.5 times sales. Electric vehicle (EV) stocks Rivian Automotive and Lucid Group, meanwhile, trade at 2.7 times sales and 7.1 times sales, respectively. But looking at the robotaxi opportunity alone, Tesla's premium could be worth it. Cathie Wood, CEO of Ark Investment Management, believes the robotaxi market will be huge. "We think $8 to $10 trillion for the entire autonomous taxi opportunity throughout the world, from almost nothing," Wood said in March. "That's how quickly AI is going to cause these things to happen." Within the next five years, Wood predicts Tesla's share price to reach $2,600. (It closed Wednesday at $322.) More than 90% of that increase, she believes, will be due to the robotaxi opportunity. Wood is known for her bold predictions. This time, however, she's not alone. Analyst Dan Ives believes the robotaxi opportunity could add $1 trillion in value to Tesla's market cap by the end of 2026. In reality, the robotaxi opportunity will likely take years to fully play out. It could even take decades. But Tesla has two advantages that most of its competition lacks: brand recognition and access to capital. With a $950 billion market cap, Tesla can raise billions of dollars while barely diluting current shareholders. And while its brand image has taken a hit recently, surveys show that the vast majority of Tesla owners remain fanatical about the business. Tesla's robotaxi opportunity is huge. Its brand and capital advantages make it a long-term buy for robotaxi bulls. Don't miss this second chance at a potentially lucrative opportunity Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this. On rare occasions, our expert team of analysts issues a 'Double Down' stock recommendation for companies that they think are about to pop. If you're worried you've already missed your chance to invest, now is the best time to buy before it's too late. And the numbers speak for themselves: Nvidia: if you invested $1,000 when we doubled down in 2009, you'd have $447,134!* Apple: if you invested $1,000 when we doubled down in 2008, you'd have $40,090!* Netflix: if you invested $1,000 when we doubled down in 2004, you'd have $652,133!* Right now, we're issuing 'Double Down' alerts for three incredible companies, available when you join , and there may not be another chance like this anytime soon.*Stock Advisor returns as of July 14, 2025 Ryan Vanzo has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Tesla. The Motley Fool has a disclosure policy. This Opportunity Could Spell Huge Success for Tesla was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
